S5 Ep79: Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
S5 Ep79: Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
-
Narrated by:
-
By:
About this listen
Episode Highlights
“A clinical trial upfront would be my first option. After that, I have to try and find something their myeloma hasn't seen yet.”
“With CAR T, the CRS incidence is higher, and I think we're doing better [at managing it] because we have multiple interventions. We see viral infections with [both] the CAR T and the bispecifics. We always have to kind of keep that in the back of our mind.”
“The more medications we have, the more this is turning into a chronic illness.”
For More On Multiple Myeloma:
- Delivering Teclistamab in the Outpatient Setting
- Ambulation Improves Frailty Scores in Patients With Multiple Myeloma
- With New Bispecific Antibodies in Multiple Myeloma, Nurses Need To Know How to Manage CRS
Video Interviews
- Managing Teclistamab-Induced CRS for Patients With Multiple Myeloma
- Data Supporting Elranatamab Approval in Multiple Myeloma
- Data Behind Talquetamab Approval in Multiple Myeloma
More Podcast Episodes
- Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape
- ASH Data Offer Treatment Direction for Oncology Nursing Professionals
- A Look Back at 2022 FDA Approvals in Oncology
- Conversations Around Selinexor: Best Nursing Practices in Multiple Myeloma
What listeners say about S5 Ep79: Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
Average Customer RatingsReviews - Please select the tabs below to change the source of reviews.
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.